Skip to main content
. 2022 Nov 18;13(3):616–631. doi: 10.1158/2159-8290.CD-22-0659

Figure 4.

Figure 4. DELFI machine learning models detect liver cancer with high sensitivity and specificity. A, DELFI scores for the US/EU cohort across liver disease and cancer stage for the screening and surveillance models. Cirrhotic patients have DELFI scores higher than individuals without cancer or with viral hepatitis on average, but lower than all stages of liver cancer. Patients with liver cancer across all stages have relatively high DELFI scores, with stage C individuals uniformly having the highest DELFI scores. B, ROC analyses of the US/EU general population cohort and the high-risk surveillance cohort. C, ROC analyses of the US/EU general population and surveillance cohorts separated by BCLC stage, showing high sensitivity and specificity across stages. D, ROC analyses for the fixed surveillance model applied to the Hong Kong cohort, which includes 90 HCC individuals with HCC (85 with BCLC stage A cancer, and 5 with BCLC stage B cancer), 101 individuals with cirrhosis and viral hepatitis and 32 individuals without cancer or liver disease.

DELFI machine learning models detect liver cancer with high sensitivity and specificity. A, DELFI scores for the US/EU cohort across liver disease and cancer stage for the screening and surveillance models. Patients with cirrhosis have DELFI scores higher than individuals without cancer or with viral hepatitis on average, but lower than all stages of liver cancer. Patients with liver cancer across all stages have relatively high DELFI scores, with stage C individuals uniformly having the highest DELFI scores. B, ROC analyses of the US/EU general population cohort and the high-risk surveillance cohort. C, ROC analyses of the US/EU general population and surveillance cohorts separated by BCLC stage, showing high sensitivity and specificity across stages. D, ROC analyses for the fixed surveillance model applied to the Hong Kong cohort, which includes 90 individuals with HCC (85 with BCLC stage A cancer, and 5 with BCLC stage B cancer), 101 individuals with cirrhosis and viral hepatitis, and 32 individuals without cancer or liver disease.